Title

How are sociodemographic factors associated with 2020/2021 seasonal influenza vaccination behavior under the COVID-19 pandemic?

Takahiro Mori [a], Tomohisa Nagata [a], Kazunori Ikegami [b], Ayako Hino [c], Seiichiro Tateishi [d], Mayumi Tsuji [e], Shinya Matsuda [f], Yoshihisa Fujino [g], Koji Mori [a]*, for the CORoNaWork project

Affiliations:

[a] Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [b] Department of Work Systems and Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [c] Department of Mental Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [d] Department of Occupational Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [e] Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [f] Department of Public Health, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan; [g] Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan

*Correspondence author: Koji Mori, MD, PhD

Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

E-mail: kmori@med.uoeh-u.ac.jp; Tel: +81-93-603-1611; Fax: +81-93-603-2155

Abstract

The 2020/2021 seasonal influenza vaccination was carried out under unique situations during the coronavirus disease 2019 (COVID-19) pandemic. Examining the factors affecting vaccine inoculation in a pandemic situation may provide valuable insights. The purpose of the current study was to investigate how the COVID-19 pandemic affected the 2020/2021 seasonal influenza vaccine intake. A cross-sectional study was conducted on workers aged 20–65 years on December 22–25, 2020, using data from an Internet survey. We set the presence or absence of 2020/2021 seasonal influenza vaccination as the dependent variable, and each aspect of sociodemographic factors, including gender, age, marital status, education, annual household income, and underlying disease, as independent variables. We performed a multilevel logistic regression analysis nested by residence. In total, 26,637 respondents (13,600 men, 13,037 women) participated, and a total of 11,404 individuals (42.8%) received the 2020/2021 influenza vaccine. Significantly more women than men were vaccinated, and the vaccination rate was higher among younger adults, married people, highly educated people, high-income earners, and those with underlying disease. The current results suggested that the relationship between seasonal influenza vaccination behavior and sociodemographic factors differed from the results reported in previous studies in terms of age. These findings suggest that, during the COVID-19 pandemic, young people may have become more aware of the risk of contracting influenza and of the effectiveness of the influenza vaccine. In addition, information interventions may have had a positive effect.

Key words: Seasonal influenza vaccine, COVID-19 pandemic, Sociodemographic factors, Risk perception, Vaccine efficacy, Information intervention

Introduction

The Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2, and the 2020/2021 seasonal influenza vaccination, which was started in the fall of 2020 when the development of the pandemic vaccine was urgently under way, share major symptomatic characteristics. Because the main complaints of influenza are fever and malaise, it is difficult to distinguish it from COVID-19 based on symptoms alone, and to diagnose COVID-19, nucleic acid amplification tests such as real-time reverse transcription–polymerase chain reaction (RT-PCR) or antigen tests are required.[1] In Japan, although the number of infected people was small in comparison with other countries, the implementation system of tests for diagnosis was insufficient around the fall of 2020. If there was a strong suspicion of a new coronavirus infection after receiving instructions from a public health center or seeing an attending physician, the patient was mandated to undergo tests such as RT-PCR, the results of which were not immediately known.[2] In addition, owing to the small number of infected people, those infected and their close contacts tended to be given special attention. In some cases, the workplace ordered them to remain at home longer than necessary. So, the 2020/2021 seasonal influenza vaccination was recommended for the purpose of preventing influenza, which is difficult to distinguish from COVID-19.[3]

Influenza vaccination is the most effective way to protect against seasonal influenza infections. Influenza is a common acute respiratory infection that can lead to hospitalization, and, in severe cases, death. Individuals at high risk of serious complications of influenza include people with asthma, chronic lung disease, diabetes mellitus, chronic heart disease, chronic kidney disease, stroke, obesity, central nervous system degeneration, immunosuppression, adults 65 years and older, children younger than 2 years old, and pregnant women.[4] Many previous studies have reported that influenza vaccines have a range of benefits, including reducing the risk of influenza infection, hospitalization, and death, and inoculation is recommended, particularly for high-risk individuals.[4-7] However, the influenza vaccination rate for individuals at high risk is 50% or less in many countries.[8] In Japan, the inoculation rate for people aged 65 and over is less than 50%, and the inoculation rate for people under the age of 65 years is even lower.[8-10]

Kini et al. reviewed papers investigating the effects of age, gender, and race on seasonal influenza vaccination. Age was found to be directly related to vaccine intention, with vaccination rates increasing with age. Women were found to be more likely to receive the

influenza vaccine, as were white populations.[11] Schmid et al. reviewed papers from the
2005–2016 period covering the factors that influence influenza vaccine inoculation, and it has
been reported that living alone, not being married, and having no diseases under treatment are
associated with non-vaccination.[12]

In the 2020/2021 season, the expectation regarding the efficacy of the influenza vaccine
included not only the prevention of influenza itself, but also the possibility of being treated as
COVID-19.[3] The vaccine itself is a widely used seasonal influenza vaccine, and the associated
risk of adverse reactions is relatively well known. Investigating the factors influencing
seasonal influenza vaccination during the COVID-19 pandemic may provide useful insights
for improving the vaccination rate. The purpose of the current study was to investigate how
the unique characteristics of the COVID-19 pandemic affected the 2020/2021 seasonal
influenza vaccine intake.

Materials and methods

Study design

This cross-sectional study was conducted using data from a baseline study of a prospective
cohort study called the Collaborative Online Research on the Novel-coronavirus and Work
(CORoNaWork). This survey was conducted as a self-administered questionnaire by Internet
research company Cross Marketing (Tokyo, Japan) to investigate the health status of workers
from December 22 to December 26, 2020, when the third wave of the COVID-19 pandemic
was circulating in Japan [13]. Details of the protocol have already been reported. Participants
were workers aged 20 to 65 years at the time of the survey and were stratified by cluster
sampling according to gender, age, and region of residence. After participants with
insufficient responses were excluded, 27,036 individuals were enrolled. We then excluded 195
people infected with COVID-19 and 204 who were close contacts, meaning that 26,637 were
finally available for analysis. This study was approved by the Ethics Committee of the
University of Occupational and Environmental Health, Kitakyushu, Japan (Approval No.
R2-079).

Assessment of the 2020/2021 seasonal influenza vaccination

Regarding the 2020/2021 seasonal influenza vaccination, we asked participants "Did you
receive this season's influenza vaccine?," to which they answered "Yes" or "No."

Assessment of sociodemographic factors

Regarding sociodemographic factors, we investigated gender, age (20–29, 30–39, 40–49,

50–59, and 60–65 years), marital status (single; divorced or widowed; married), education

(junior high school or high school; vocational school or college; university or graduate

school), annual household income (<2.00 million Japanese yen [JPY]; 2.00–3.99 million JPY;

4.00–7.99 million JPY; ≥8.00 million JPY), and underlying disease, for which we asked the

question, "Do you have any disease that requires regular visits to the hospital or treatment?"

Participants selected one of the following: "I do not have such a disease," "I am receiving

hospital visits and treatment as scheduled," or "I am not receiving hospital visits and

treatment as scheduled." We rated the participants who answered, "I do not have such a

disease" as "No" and the remaining two answers as "Yes."

Statistical analysis

Seasonal influenza vaccination rates were calculated for all variables. We set the presence or

absence of 2020/2021 seasonal influenza vaccination as the dependent variable, and each

aspect of sociodemographic factors consisting of gender, age, marital status, education, annual

household income, and underlying disease as independent variables. Multivariate adjusted

odds ratios (ORs) were estimated using multilevel logistic regression analysis. The

multivariate model was adjusted for all covariates. Considering the influence of regional

differences in the infection status of COVID-19, all analyses were performed by multilevel

analysis nested by prefecture of residence. A *P* values of less than 0.05 were considered

statistically significant. All analyses were performed using STATA Version 16 (StataCorp,

College Station, TX, USA).

Results

Table 1 shows the characteristics of the participants. A total of 26,637 people (13,600 men

and 13,037 women) were analyzed. In each variable, 50–59 years old (8,909: 33.5%), married

(14,794: 55.4%), annual household income of 4.00-7.99 million JPY (11,759: 48.2%), and

university or graduate school (12,956: 48.6%) provided the largest numbers. There were 9,346

people (35.1%) with underlying disease. A total of 11,404 individuals (42.8%) received the

2020/2021 influenza vaccine.

Table 2 shows the sociodemographic factors associated with receiving the 2020/2021 seasonal

influenza vaccine. In the multivariate adjusted model, significantly more women than men

161 were vaccinated (aOR 1.52, 95% CI 1.43–1.61). Compared with people aged 20–29, those

162 aged 30–39 (aOR 0.88, 95% CI 0.79–0.99), 40–49 (aOR 0.68, 95% CI 0.61–0.76), 50–59

163 (aOR 0.64, 95% CI 0.57–0.71), and 60–65 (aOR 0.72, 95% CI 0.63–0.82) had lower

164 vaccination rates. Married people were more likely to be vaccinated than single people (aOR

165 1.72, 95% CI 1.61–1.83), and more vaccinations were administered to individuals with higher

166 levels of education, and those with higher annual household income. In addition, individuals

167 with underlying diseases were also more likely to be vaccinated (aOR 1.55, 95% CI

168 1.47–1.64). (Table 2).

170 **Discussion**

171 The COVID-19 pandemic constitutes a unique situation in which the expectations for the

172 efficacy of the 2020/2021 seasonal influenza vaccine included the prevention of not only

173 influenza itself, but also the possibility of being treated as COVID-19. We investigated the

174 effects of socioeconomic factors on seasonal influenza vaccine inoculation in this context.

175 The results revealed that the influenza vaccination rate was higher among women, younger

176 adults, married people, highly educated people, high-income earners, and those with

177 underlying disease.

179 A review by Kini et al. reported that women were more likely to receive the seasonal

180 influenza vaccine and that older people had higher vaccination rates than young people.[11] In

181 addition, it has reported that not being married was associated with non-vaccination, whereas

182 higher levels of education and the presence of chronic diseases increased the likelihood of

183 vaccination.[12,14] Thus, other than age, the current results were consistent with previous reports

184 regarding sociodemographic factors.

186 Previous studies have suggested various factors that may contribute to the higher vaccination

187 rates observed among older people. Because older people are more likely to have chronic

188 disease, vaccinations are often recommended by their physicians. Older people are also more

189 likely to have had the influenza infection in the past, and to believe in the benefits of

190 vaccination.[15,16] In contrast, many young people have little knowledge about the risks of

191 contracting influenza or about vaccine efficacy, and they often do not receive vaccine

192 recommendations, have fewer opportunities to obtain such information, or ignore information

193 that is provided.[15,17] In addition, adverse reactions following vaccination, including local and

194 systematic symptoms, have been more frequently reported in younger people, which has

contributed to lower vaccination rates among young people.[11]

The results of the current study suggest that young people became more aware of the risk of
contracting influenza during the COVID-19 pandemic, potentially resulting in higher
vaccination rates. If contracting influenza, it was necessary to consult a medical institution or
contact a health center in a situation whereby it was difficult to distinguish influenza from
COVID-19, complicated by problems that occurred in the diagnostic process and results. At
the time of the survey in Japan, where the number of infected people was smaller than in
Western countries and the establishment of testing systems such as RT-PCR was delayed, it
took time to make a definitive diagnosis and there was also prejudice against infected
people.[12] Thus, risk perception among young people may have increased. Risk perception has
a great influence on vaccination intention. A meta-analysis of 34 papers, including studies on
influenza vaccines, showed that the higher is risk perception, the greater is the number of
vaccinations.[18] Young people may have also become more aware of the effectiveness of the
seasonal influenza vaccine. Vaccination decisions are typically made by comparing the
positive and negative aspects of vaccination, such as the efficacy of the vaccine and the risks
of side effects.[19] An important aspect of the 2020/2021 seasonal influenza vaccine was that
the perceived efficacy included preventing not only influenza itself but also the possibility of
preventing COVID-19, as described above.[3] Although young people are more likely to
experience the side effects of the vaccine,[11] it is possible that awareness of vaccine efficacy
outweighed concerns about side-effects. We speculate that these changes in young people may
have been influenced by information regarding vaccine efficacy being effectively provided to
many young people through government announcements, media such as TV and the internet,
and possibly in the workplace.

Regarding factors other than age, women, married people, highly educated people,
high-income earners, and those with underlying diseases exhibited higher vaccination rates in
the current study, which was similar to results reported in previous studies.[11,12,14] These results
suggest that the effects of these factors on seasonal influenza vaccination did not change, even
in the unique context of the COVID-19 pandemic.

Overall, the annual influenza vaccination rate for the Japanese population is reported to be
around 30%–40% for adults under the age of 65 years,[9,10] and in this study conducted in
December the vaccination rate was already slightly higher than was stated in these reports.

This may be due to the relatively high risk of contracting seasonal influenza under the
COVID-19 pandemic, resulting in increased perception of vaccine efficacy, particularly
among young people. This result indicates that the seasonal influenza vaccination rate
increased in young people who usually have a relatively low inoculation rate. This finding
may have important implications. Education about the risk of infectious diseases is likely to
have contributed to this result, and information about vaccine efficacy and the risk of side
effects of the vaccine was effectively provided and understood. This finding may be useful for
informing initiatives to improve vaccination rates in the future.

The main strength of the current study was the large sample size. However, two main
limitations were involved in the current study. First, because we conducted an Internet survey,
selection bias might have occurred. Although we stratified by cluster sampling according to
gender, age, and region of residence at the beginning of the survey to reduce bias, the survey
was intended for people registered as an online survey panel and was not representative of the
general population. Second, regarding influenza vaccination, we asked subjects whether they
were vaccinated between December 22 and 26 in 2020, when the survey was conducted;
therefore, those who were vaccinated after that time and those scheduled to be vaccinated
were not included. In particular, the 2020/2021 influenza vaccine has been in short supply in
some areas and medical institutions owing to high demand for vaccination because of the
influence of the COVID-19 pandemic, and in some cases, there was a long waiting time
before inoculation. However, since vaccination started at the end of October in Japan, it was
probable that those who had decided to be inoculated had collected information on supply
shortages and made reservations and vaccinations early.

In conclusion, in a situation in which the rate of seasonal influenza vaccination increased
during the COVID-19 pandemic, the relationships between seasonal influenza vaccination
behavior and sociodemographic factors differed from the findings of previous studies in terms
of age. Our results suggest that young people may have become more aware of the risks of
contracting influenza during the COVID-19 pandemic, and of the effectiveness of the
seasonal influenza vaccine. This increased awareness may have resulted in higher vaccination
rates. We speculate that information interventions contributed to this result. We believe that
these findings provide useful insight for improving the influenza vaccination rate.

Acknowledgments

We thank the current members of the CORoNaWork Project, in alphabetical order, are as
follows: Dr. Yoshihisa Fujino (present chairperson of the study group), Dr. Akira Ogami, Dr.
Arisa Harada, Dr. Ayako Hino, Dr. Chimed-Ochir Odgerel , Dr. Hajime Ando, Dr. Hisashi
Eguchi, Dr. Kazunori Ikegami, Dr. Keiji Muramatsu, Dr. Koji Mori, Dr. Kosuke Mafune, Dr.
Kyoko Kitagawa, Dr. Masako Nagata, Dr. Mayumi Tsuji, Dr. Rie Tanaka, Dr. Ryutaro
Matsugaki, Dr. Seiishiro Tateishi, Dr. Shinya Matsuda, Dr. Tomohiro Ishimaru, Dr. Tomohisa
Nagata, and Ms. Ning Liu. All members are affiliated with the University of Occupational and
Environmental Health, Japan.

Funding details
This study was funded by a research grant from the University of Occupational and
Environmental Health, Japan; a general incorporated foundation (Anshin Zaidan) for the
development of educational materials on mental health measures for managers at small-sized
enterprises; Health, Labour and Welfare Sciences Research Grants: Comprehensive Research
for Women's Healthcare (H30-josei-ippan-002) and Research for the establishment of an
occupational health system in times of disaster (H30-roudou-ippan-007); consigned research
foundation (the Collabo-health Study Group); and scholarship donations from Chugai
Pharmaceutical Co., Ltd.

Disclosure statement
The authors declare no conflict of interest.

Reference
1. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2
(COVID-19).   [accessed   2021   Aug   18].
https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
2. Ministry of Health, Labour and Welfare, Japan. Establishing a system to prepare for the
next influenza pandemic [In Japanese]. Tokyo; 2020 Sep 10 [accessed 2021 Aug 18].
https://www.mhlw.go.jp/content/10906000/000670405.pdf
3. Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, Atmar RL.
Prevention and control of seasonal influenza with vaccines: Recommendations of the
advisory committee on immunization practices-United States, 2020-21 influenza season.
MMWR Recomm Reports 2020;69:1-24. doi: 10.15585/mmwr.rr6908a1.
4. Centers for Disease Control and Prevention. People at High Risk For Flu Complications.

[accessed 2021 Aug 18]. https://www.cdc.gov/flu/highrisk/index.htm

5. Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical visits,

and Hospitalizations Averted by Vaccination in the United States — 2019–2020 Influenza

Season. [accessed 2021 Aug 18].

https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm

6. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG.

Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A

systematic review and meta-analysis of test-negative design case-control studies. J Infect

2017;75:381-94. doi: 10.1016/j.jinf.2017.09.010.

7. Thompson MG, Pierse N, Sue Huang Q, Prasad N, Duque J, Claire Newbern E, Baker

MG, Turner N, McArthur C; SHIVERS investigation team. Influenza vaccine

effectiveness in preventing influenza-associated intensive care admissions and attenuating

severe disease among adults in New Zealand 2012–2015. Vaccine 2018;36:5916-25. doi:

10.1016/j.vaccine.2018.07.028.

8. Organisation for Economic Co-operation and Development. Influenza vaccination rates

(indicator). Paris: 2021. doi: 10.1787/e452582e-en (Accessed 2021 August 13)

9. National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases

Control Division, Ministry of Health, Labour and Welfare. Influenza vaccination

coverage and seroprevalence of influenza, Japan-FY 2018, National Epidemiological

Surveillance of Vaccine–Preventable Diseases [In Japanese]. IASR 2019;40:188-190.

10. National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases

Control Division, Ministry of Health, Labour and Welfare. Influenza vaccination

coverage and seroprevalence of influenza, Japan-FY 2019, National Epidemiological

Surveillance of Vaccine–Preventable Diseases [In Japanese]. IASR 2020;41:201-204.

11. Kini A, Morgan R, Kuo H, Shea P, Shapiro J, Leng SX, Pekosz A, Klein SL. Differences

and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage

by age, sex, gender, and race. Vaccine 2021. doi.org/10.1016/j.vaccine.2021.04.013.

12. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination

Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 –

2016. PLoS One 2017;12:e0170550. doi.org/10.1371/journal.pone.0170550.

13. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, Mori K, Matsuda S.

Protocol for a nationwide Internet-based health survey in workers during the COVID-19

pandemic in 2020. JUOEH 2021:in press. doi.org/10.1101/2021.02.02.21249309.

14. Brien S, Kwong JC, Buckeridge DL. The determinants of 2009 pandemic A/H1N1

influenza vaccination: A systematic review. Vaccine 2012;30:1255–64. doi.org/10.1016/j.vaccine.2011.12.089.

15. Nowak GJ, Cacciatore MA, Len-Ríos ME. Understanding and increasing influenza vaccination acceptance: insights from a 2016 National Survey of U. S. Adults. Int J Environ Res Public Health 2018;15. 711. doi.org/10.3390/ ijerph15040711.

16. Quinn SC, Jamison A, An J, Freimuth VS, Hancock GR, Musa D. Breaking down the monolith: understanding flu vaccine uptake among African Americans. SSM Popul Heal 2018;4:25–36. doi.org/10.1016/j. ssmph.2017.11.003.

17. Roy M, Sherrard L, Dubé È, Gilbert NL. Determinants of non-vaccination against seasonal influenza. Heal Reports 2018;29:12–22.

18. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-analysis of the relationship between risk perception and health behavior: The example of vaccination. Heal Psychol 2007;26:136–45. doi.org/10.1037/0278-6133.26.2.136.

19. Tsutsui Y, Benzion U, Shahrabani S, Din GY. A policy to promote influenza vaccination: A behavioral economic approach. Health Policy 2010;97:238–49. doi.org/10.1016/j.healthpol.2010.05.008.

Table 1. Characteristics of the participants

	Total n=26637
Gender	
Men	13600 (51.1%)
Women	13037 (48.9%)
Age (years)	
20–29	1850 (7.0%)
30–39	4762 (17.9%)
40–49	7904 (29.7%)
50–59	8909 (33.5%)
60–65	3212 (12.1%)
Marital status	
Single	9034 (33.9%)
Divorced or widowed	2809 (10.6%)
Married	14794 (55.4%)
Education	
Junior high or high school	7240 (27.2%)
Vocational school or college	6441 (24.2%)
University or graduate school	12956 (48.6%)
Annual household income (JPY)	
<2.00 million	1685 (6.3%)
2.00–3.99 million	5487 (20.6%)
4.00–7.99 million	11759 (48.2%)
≥8.00 million	7706 (28.9%)
Underlying disease	
No	17291 (64.9%)
Yes	9346 (35.1%)
Receiving 2020/2021 seasonal influenza vaccine	
No	15233 (57.2%)
Yes	11404 (42.8%)

JPY, Japanese yen

Table 2. Sociodemographic factors associated with receiving 2020/2021 seasonal influenza vaccine

	n	%[a]	Crude			Multivariate adjusted*		
			OR	95% CI	P value	OR	95% CI	P value
Gender								
Men	5310	39.0	1.00	–	–	1.00		
Women	6094	46.7	1.37	1.31–1.44	<0.001	1.52	1.43–1.61	<0.001
Age (years)								
20–29	908	49.1	1.00	–	–	1.00	–	
30–39	2294	48.2	0.97	0.87–1.08	0.619	0.88	0.79–0.99	0.031
40–49	3226	40.8	0.73	0.66–0.80	<0.001	0.68	0.61–0.76	<0.001
50–59	3558	39.9	0.71	0.64–0.78	<0.001	0.64	0.57–0.71	<0.001
60–65	1418	44.1	0.84	0.75–0.95	0.004	0.72	0.63–0.82	<0.001
Marital status								
Single	3233	35.8	1.00	–	–	1.00	–	
Divorced or widowed	1113	39.6	1.16	1.07–1.27	0.001	1.33	1.21–1.46	<0.001
Married	7058	47.7	1.62	1.53–1.70	<0.001	1.72	1.61–1.83	<0.001
Education								
Junior high or high school	2609	36.0	1.00	–	–	1.00	–	
Vocational school or college	2940	45.6	1.53	1.43–1.64	<0.001	1.40	1.31–1.51	<0.001
University or graduate school	5855	45.2	1.53	1.44–1.63	<0.001	1.41	1.32–1.50	<0.001
Annual household income (JPY)								
<2.00 million	441	26.2	1.00	–	–	1.00	–	
2.00–3.99 million	2,034	37.1	1.65	1.46–1.87	<0.001	1.60	1.41–1.81	<0.001
4.00–7.99 million	5,145	43.8	2.19	1.95–2.45	<0.001	1.93	1.71–2.17	<0.001
≥8.00 million	3,784	49.1	2.76	2.45–3.11	<0.001	2.28	2.01–2.58	<0.001
Underlying disease								
No	6861	39.7	1.00	–	–	1.00	–	
Yes	4543	48.6	1.43	1.36–1.50	<0.001	1.55	1.47–1.64	<0.001

*Adjusted for gender, age, marital status, educational background, annual household income, and underlying disease
[a]Row proportions for influenza vaccination
OR, odds ratio; CI, confidence interval; JPY, Japanese yen